Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Cancer Institute (NCI) is inviting applications for Research Units (RUs) under the Pancreatic Cancer Detection Consortium (PCDC) to advance research focused on the early detection of pancreatic ductal adenocarcinoma (PDAC) and its precursor lesions. The goal is to identify patients at high risk of cancer progression by developing and testing new molecular and imaging biomarkers for early diagnosis. This initiative supports one of the key research priorities in the NCI’s 2014 Scientific Framework for PDAC. The RUs will be multi-disciplinary teams tasked with identifying biomarkers in bodily fluids, developing molecular and imaging markers to evaluate pancreatic cysts, creating approaches for screening high-risk populations, employing machine learning techniques for biomarker discovery and validation, and conducting related validation studies. In addition, the RUs will build a longitudinal biorepository and actively collaborate within the consortium by sharing data, biospecimens, and ideas. Complementing these research efforts, the PCDC will include a Management and Data Coordination Unit, responsible for supporting study design, protocol development, statistical analysis, coordination, data management, and stewardship of collaborative projects, including the biorepository. The contract aims to foster a collaborative environment to enhance early detection methods for PDAC, facilitating early intervention strategies for at-risk individuals based on genetic, familial, or lesion-related factors. The opportunity is managed by the National Institutes of Health within the Department of Health and Human Services, with further details accessible through the provided grant portal.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
Through this Notice of Funding Opportunity (NOFO), NCI solicits applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify patients who are at high risk of progression to cancer. The PCDC will continue to address one of the four research priorities identified in the NCI's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma (PDAC). The PCDC will support research for the development and testing of new molecular and imaging biomarkers for detecting PDAC early and for identifying patients at high risk of PDAC (because of genetic factors, family history and/or the presence of precursor lesions) who could be candidates for early intervention.
The PCDC-RUs will consist of multi-disciplinary teams and will undertake studies to: identify and test biomarkers measurable in bodily fluids for early detection of PDAC and/or its precursor lesions; develop molecular- and/or imaging-based markers of pancreatic cysts and determine which lesions are likely to progress to cancer; develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC; use machine learning and computational approaches towards biomarker discovery and/or validation; and conduct biomarker validation studies. The PCDC-RUs will also collect longitudinal biospecimens for building a biorepository. Each PCDC-RU is expected to participate in collaborative activities with other PCDC-RUs and share ideas, biospecimens, and data within the Consortium.
The other scientific component of the PCDC will be the Management and Data Coordination Unit, which will provide support toward study design, protocol development, statistical analysis, coordination, harmonization, data management and stewardship for the trans-PCDC collaborative projects, including biorepository building effort.
